Clinical Research Directory

Inclusion Criteria: * Male or female, age \>= 18 years, with life expectancy of at least 12 weeks. * Patients with histologically documented metastatic (stage IV) non-small cell lung cancer. * Subjected to driving genes examination including EGFR, ALK and ROS1. * Achieve complete response (CR)/partial response (PR)/stable disease (SD) after front line systemic treatment (chemotherapy, targeted therapy or immunological checkpoint inhibitors). * Total metastatic lesions is limited to five. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of \<= 2. * Patients must have measurable disease according to the RECIST (version 1.1) criteria. * Adequate organ function as defined by the following criteria: * Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<= 2.5 upper limit of normal (ULN) in the absence of liver metastases or up to 5 ULN in case of liver metastases. Total bilirubin \<= 1.5 ULN. * Bone marrow function: Granulocyte count \>= 1,500/mm3 and platelet count ≥100,000/mm3 and hemoglobin \>= 80g/dl. * Renal function: serum creatinine \<= 1.5 ULN or creatinine clearance \>= 60 ml/min. (based on modified Cockcroft-Gault formula). * Adequate coagulating function. * For all females of childbearing potential a negative serum/urine pregnancy test must be obtained within 48 hours before enrollment. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Males must agree to use effective contraception during the study period and for at least 12 weeks after completion of the study treatment. * Written (signed) informed Consent to participate in the study. * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: * Stage I-III a NSCLC completing radical treatment , then undergoing systemic anti-cancer treatment after recurrence. * Patients with PFS no more than 3 months. to first line theray. * Patients with history of any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer). * Prior palliative surgery or other local therapy specifically directed against advanced lung cancer. * Contraindication for localized treatment including surgery, radiotherapy or interventional therapy judged by physicians. * Patients with any unstable systemic disease (including active infections, significant cardiovascular disease, any significant hepatic, renal or metabolic disease). * Patients who are at risk (in the investigator's opinion) of transmitting human immunodeficiency virus (HIV) through blood or other body fluids. * Nursing or lactating women. * Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study. * Patients who has mental disorder or other disease that contribute to no compliance. * Unwilling to write informed consent to participate in the study. * Patients who is unwilling to accept the follow-up.